vs
ASP Isotopes Inc.（ASPI）与Sol-Gel Technologies Ltd.（SLGL）财务数据对比。点击上方公司名可切换其他公司
Sol-Gel Technologies Ltd.的季度营收约是ASP Isotopes Inc.的1.0倍（$17.3M vs $16.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs 217.7%）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Sol-Gel Technologies Ltd.是一家专注皮肤科药物研发的专业生物制药企业，依托专有溶胶凝胶递送技术开发痤疮、玫瑰痤疮、特应性皮炎等常见皮肤疾病的外用治疗方案，核心市场覆盖北美与欧洲，与医疗行业知名企业合作推进产品商业化。
ASPI vs SLGL — 直观对比
营收规模更大
SLGL
是对方的1.0倍
$16.7M
营收增速更快
ASPI
高出1078.0%
217.7%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $17.3M |
| 净利润 | — | $11.6M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | 65.1% |
| 净利率 | — | 67.3% |
| 营收同比 | 1295.7% | 217.7% |
| 净利润同比 | -586.8% | 487.6% |
| 每股收益（稀释后） | — | $4.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPISLGL
| Q4 25 | $16.7M | — | ||
| Q3 25 | $4.9M | — | ||
| Q2 25 | — | $17.3M | ||
| Q2 24 | — | $5.4M | ||
| Q2 23 | — | $594.0K | ||
| Q2 22 | — | $3.5M |
净利润ASPISLGL
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | — | ||
| Q2 25 | — | $11.6M | ||
| Q2 24 | — | $2.0M | ||
| Q2 23 | — | $-6.0M | ||
| Q2 22 | — | $-134.0K |
毛利率ASPISLGL
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
营业利润率ASPISLGL
| Q4 25 | — | — | ||
| Q3 25 | -306.1% | — | ||
| Q2 25 | — | 65.1% | ||
| Q2 24 | — | 29.9% | ||
| Q2 23 | — | -1098.8% | ||
| Q2 22 | — | -13.2% |
净利率ASPISLGL
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | — | ||
| Q2 25 | — | 67.3% | ||
| Q2 24 | — | 36.4% | ||
| Q2 23 | — | -1005.1% | ||
| Q2 22 | — | -3.8% |
每股收益（稀释后）ASPISLGL
| Q4 25 | — | — | ||
| Q3 25 | $-0.15 | — | ||
| Q2 25 | — | $4.17 | ||
| Q2 24 | — | $0.71 | ||
| Q2 23 | — | $-0.22 | ||
| Q2 22 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $24.3M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $31.9M |
| 总资产 | $498.0M | $39.3M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPISLGL
| Q4 25 | $333.3M | — | ||
| Q3 25 | $113.9M | — | ||
| Q2 25 | — | $24.3M | ||
| Q2 24 | — | $26.5M | ||
| Q2 23 | — | $33.5M | ||
| Q2 22 | — | $15.6M |
总债务ASPISLGL
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
股东权益ASPISLGL
| Q4 25 | $204.2M | — | ||
| Q3 25 | $74.1M | — | ||
| Q2 25 | — | $31.9M | ||
| Q2 24 | — | $34.9M | ||
| Q2 23 | — | $48.3M | ||
| Q2 22 | — | $50.4M |
总资产ASPISLGL
| Q4 25 | $498.0M | — | ||
| Q3 25 | $225.9M | — | ||
| Q2 25 | — | $39.3M | ||
| Q2 24 | — | $42.0M | ||
| Q2 23 | — | $55.1M | ||
| Q2 22 | — | $55.0M |
负债/权益比ASPISLGL
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | — |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | — |
| 自由现金流率自由现金流/营收 | -284.7% | — |
| 资本支出强度资本支出/营收 | 57.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPISLGL
| Q4 25 | $-37.8M | — | ||
| Q3 25 | $-8.9M | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | $-8.3M | ||
| Q2 22 | — | — |
自由现金流ASPISLGL
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | $-8.4M | ||
| Q2 22 | — | — |
自由现金流率ASPISLGL
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | -1419.0% | ||
| Q2 22 | — | — |
资本支出强度ASPISLGL
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | 15.8% | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
